Core Viewpoint - Evogene Ltd. has announced a warrant inducement transaction that will generate approximately $3.4 million in gross proceeds through the immediate exercise of existing warrants, aimed at enhancing its working capital and supporting general corporate purposes [1]. Group 1: Warrant Inducement Transaction - The company entered into a warrant inducement agreement with an existing institutional investor for the immediate exercise of Series A and Series B ordinary warrants, allowing the purchase of up to 1,692,308 ordinary shares each [1]. - The existing warrants will be exercised at a reduced price of $1.00 per share, resulting in total gross cash proceeds of approximately $3.4 million before expenses [1]. - In exchange for the immediate exercise of the existing warrants, the investor will receive new Series A-1 and Series B-1 unregistered warrants, each allowing the purchase of up to 2,538,462 ordinary shares at an exercise price of $1.25 per share [1]. Group 2: Use of Proceeds and Financial Advisory - The net proceeds from the transaction are intended for working capital and other general corporate purposes [1]. - A.G.P./Alliance Global Partners is acting as the sole financial advisor for this transaction [1]. Group 3: Regulatory and Compliance Information - The new warrants were offered in a private placement under an exemption from the registration requirements of the Securities Act of 1933, and the company plans to file a registration statement with the SEC for the resale of ordinary shares upon exercise of the new warrants [1].